MD 18
Alternative Names: MD-18Latest Information Update: 28 Feb 2025
Price :
$50 *
At a glance
- Originator Radella Pharmaceuticals
- Class Obesity therapies; Peptides
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
Most Recent Events
- 02 Jan 2025 Radella Pharmaceuticals initiates enrolment in a phase I trial for Obesity in Israel (SC, Injection) (NCT06739707)
- 18 Dec 2024 Radella Pharmaceiticals plans a phase I trial for Obesity and Diabetes mellitus (In volunteers) in December 2024 (SC) (NCT06739707)
- 07 Nov 2024 Radella Pharmaceuticals plans a phase Ib trial for Obesity (SC) before end of 2024